OPTImal Management of Antithrombotic Agents: OPTIMA-5
Status:
Recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, open-label clinical trial which will enroll 80 acute
coronary syndrome (ACS) patients after Percutaneous Transluminal Coronary Intervention (PCI)
in China. Patients on maintenance dosing (MD) of aspirin (100 mg/d) and ticagrelor (90 mg
twice daily) will be divided into two groups switching from ongoing ticagrelor to clopidogrel
600 mg loading dose (LD)/ 75 mg MD according to their bleeding risk. Then each group will
randomly switch at different times(24 hours/ 12 hours after the last MD of ticagrelor).
Pharmacodynamic assessments are performed at baseline, and at 4h, 8h, 24h, 48h, 72h hours
with platelet aggregation rate by Light Transmittance Aggregometry method (LTA). All patients
are followed-up for 30 days.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University